BIGG

Risankizumab for previously treated moderately to severely active Crohn's disease

England. National Institute for Health and Care Excellence.

Ano de publicação: 2023

Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

Crohn Disease/drug therapy, Antibodies, Monoclonal, Humanized/therapeutic use, Health Care Costs, Network Meta-Analysis as Topic

Texto completo